Anebulo Pharmaceuticals, Inc. (ANEB)
USD 1.23
(-6.11%)
USD 1.23
(-6.11%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 8.3 Million | 11.78 Million | 6.83 Million | 3.61 Million | 173.35 Thousand |
| Selling, General and Administrative Expenses | 4.75 Million | 6.18 Million | 3.86 Million | 1.34 Million | 23.35 Thousand |
| Research and Development Expenses | 3.54 Million | 5.6 Million | 2.96 Million | 2.26 Million | 150 Thousand |
| Other Expenses | - | -41.14 Thousand | -1777.00 | -1344.00 | - |
| Cost and Expenses | 8.3 Million | 11.78 Million | 6.83 Million | 3.61 Million | 173.35 Thousand |
| Operating Income | -8.3 Million | -11.78 Million | -6.83 Million | -3.61 Million | -173.35 Thousand |
| Interest Expense | - | - | 7332.00 | 11.76 Thousand | 1286.00 |
| Income Tax Expense | - | -104.19 Thousand | -12.88 Thousand | 10.74 Thousand | -1040.11 |
| Earnings before Tax | -8.2 Million | -11.73 Million | -6.82 Million | -30.25 Million | -174.63 Thousand |
| Net Income | -8.2 Million | -11.73 Million | -6.81 Million | -30.26 Million | -174.63 Thousand |
| Earnings Per Share Basic | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| Earnings Per Share Diluted | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| Weighted Average Shares Outstanding | 25.82 Million | 25.07 Million | 23.34 Million | 23.34 Million | 23.71 Million |
| Weighted Average Shares Outstanding (Diluted) | 25.82 Million | 25.07 Million | 23.34 Million | 23.34 Million | 23.71 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | -8.05 Million | -11.78 Million | 5555.00 | -30.24 Million | -173.35 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 1.34 Million | 1.66 Million | 2.76 Million | 2.54 Million | 11.78 Million | 2.49 Million |
| Selling, General and Administrative Expenses | 872.66 Thousand | 915.91 Thousand | 1.69 Million | 1.27 Million | - | 1.07 Million |
| Research and Development Expenses | 467.7 Thousand | 748.33 Thousand | 1.06 Million | 1.27 Million | - | 1.41 Million |
| Other Expenses | -124.00 | 2321.00 | -594.00 | 7657.00 | -41.14 Thousand | -1197.00 |
| Cost and Expenses | 1.34 Million | 1.66 Million | 2.76 Million | 2.54 Million | 11.78 Million | 2.49 Million |
| Operating Income | -1.34 Million | -1.66 Million | -2.76 Million | -2.54 Million | -11.78 Million | -2.49 Million |
| Interest Expense | 59.69 Thousand | 59.69 Thousand | 31.83 Thousand | - | - | 52.45 Thousand |
| Income Tax Expense | 9478.00 | -1.66 Million | -2760.46 | -57.74 Thousand | -104.19 Thousand | 52.45 Thousand |
| Earnings before Tax | -1.34 Million | -1.65 Million | -2.71 Million | -2.48 Million | -11.73 Million | -2.49 Million |
| Net Income | -1.34 Million | -1.65 Million | -2.71 Million | -2.48 Million | -11.73 Million | -2.49 Million |
| Earnings Per Share Basic | -0.05 | -0.06 | -0.11 | -0.10 | - | -0.10 |
| Earnings Per Share Diluted | -0.05 | -0.06 | -0.11 | -0.10 | - | -0.10 |
| Weighted Average Shares Outstanding | 25.82 Million | 25.93 Million | 25.78 Million | 25.63 Million | 25.07 Million | 25.63 Million |
| Weighted Average Shares Outstanding (Diluted) | 25.82 Million | 25.93 Million | 25.78 Million | 25.63 Million | 25.07 Million | 25.63 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -1.29 Million | -1.66 Million | -2.76 Million | -2.54 Million | - | -2.49 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
ANX
GPHOF
002242
SX
MCLE
CAD